These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 8281952)

  • 1. Treatment of left ventricular hypertrophy in hypertensive patients.
    Tamargo J; Delpón E; Valenzuela C
    Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
    Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
    Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of left ventricular hypertrophy.
    Cruickshank JM
    Blood Press Suppl; 1992; 1():32-3; discussion 33-4. PubMed ID: 1343270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect.
    Grandi AM; Laurita E; Solbiati F; Marchesi C; Maresca AM; Nicolini E; Guasti L; Venco A
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):207-11. PubMed ID: 17110802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical repair of hypertensive left ventricular remodeling.
    Motz WH; Scheler S; Strauer BE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 1():S32-6. PubMed ID: 1380616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regression of left ventricular hypertrophy in hypertensive heart disease].
    Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
    Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophy to failure.
    Tanser PH
    J Hum Hypertens; 1994 Sep; 8 Suppl 1():S17-20. PubMed ID: 7807508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of diastolic function after regression of left ventricular hypertrophy.
    Teniente-Valente R; Solorio S; Vargas-Salado E; Aguirre-Vázquez C; Hernández-González MA; Olvera-Lopez JA; Rodríguez-Mariscal L; Luna-Ruiz MA; Guillén Contreras JM; Murillo Ortiz BO
    Arch Cardiol Mex; 2008; 78(4):392-9. PubMed ID: 19205547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent blood pressure control: potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15 Suppl C():13C-18C. PubMed ID: 10380687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Course of the left ventricular mass in a population of 893 hypertensive patients. Effects of treatment with perindopril].
    Revel F; Gallois H; Le Coz Y; Richard R; Ollivier JP
    Ann Cardiol Angeiol (Paris); 1994 Dec; 43(10):594-9. PubMed ID: 7864552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
    He H; Li LM; Cao WH; Sun NL; Liu MZ; Hu YH
    Ann Hum Biol; 2005; 32(1):30-43. PubMed ID: 15788353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.